Vasta G R, Quesenberry M, Ahmed H, O'Leary N
Center for Marine Biotechnology, University of Maryland Biotechnology Institute, Baltimore 21202, USA.
Dev Comp Immunol. 1999 Jun-Jul;23(4-5):401-20. doi: 10.1016/s0145-305x(99)00020-8.
In recent years, a 'new' pathway for complement activation mediated by the mannose-binding lectin (MBL) has been described as a key mechanism for the mammalian acute phase response to infection. This complement activation pathway is initiated by a non-self recognition step: the binding of a humoral C-type lectin [mannose-binding lectin (MBL)] to microbial surfaces bearing 'foreign' carbohydrate determinants. The recognition factor, MBL, is associated with a serine protease [MBL-associated serine protease (MASP)] which, upon MBL binding to the microbial ligand, activates the complement component C3, leading to either (a) phagocytosis of the opsonized target via the complement receptor, or (b) humoral cell killing via assembly of the membrane attack complex. Galectins (formerly known as S-type lectins) modulate activity of the complement receptor 3 (CR3), the macrophage membrane receptor for complement components C3b and iC3b, downstream products of the MBL pathway which are covalently bound to 'target cells. Galectins also mediate macrophage- and dendrocyte-adhesion to lymphocytes activated by signaling through another C-type lectin, the L-selectin, leading to immunoglobulin-mediated responses. Thus, the functional interplay of MBL, galectins and L-selectin in the acute phase response neutralizes the microbial challenge, and lead to further adaptive immunity. Although the observation of various components of the lectin pathway in different invertebrate species demonstrates the high conservation and ancient roots of the components of innate immunity, there has previously been no evidence supporting the possibility that the integral lectin-mediated complement activation pathway is present in invertebrates. We now have evidence for the coexistence of homologs of all the pathway's key components (MBL, MASP, C3, and galectin) in the protochordate Clavelina picta, suggesting the lectin-mediated pathway of complement activation preceded the immunoglobulin pathway in evolution. Therefore, despite being 'new' to the textbooks, experimental evidence indicates that this pathway is ancient, and has been conserved intact throughout its evolution.
近年来,一种由甘露糖结合凝集素(MBL)介导的补体激活“新”途径被描述为哺乳动物对感染急性期反应的关键机制。这种补体激活途径由一个非自我识别步骤启动:一种体液中的C型凝集素[甘露糖结合凝集素(MBL)]与带有“外来”碳水化合物决定簇的微生物表面结合。识别因子MBL与一种丝氨酸蛋白酶[MBL相关丝氨酸蛋白酶(MASP)]相关联,当MBL与微生物配体结合时,该丝氨酸蛋白酶激活补体成分C3,导致(a)通过补体受体对调理后的靶标进行吞噬,或(b)通过膜攻击复合物的组装进行体液细胞杀伤。半乳糖凝集素(以前称为S型凝集素)调节补体受体3(CR3)的活性,CR3是巨噬细胞膜上补体成分C3b和iC3b的受体,C3b和iC3b是MBL途径的下游产物,它们共价结合到“靶细胞”上。半乳糖凝集素还介导巨噬细胞和树突状细胞与通过另一种C型凝集素L-选择素信号激活的淋巴细胞的黏附,从而导致免疫球蛋白介导的反应。因此,MBL、半乳糖凝集素和L-选择素在急性期反应中的功能相互作用中和了微生物挑战,并导致进一步的适应性免疫。尽管在不同的无脊椎动物物种中观察到凝集素途径的各种成分,这表明先天免疫成分具有高度保守性和古老根源,但以前没有证据支持无脊椎动物中存在完整的凝集素介导的补体激活途径的可能性。我们现在有证据表明,原索动物皮氏柄海鞘中存在该途径所有关键成分(MBL、MASP、C3和半乳糖凝集素)的同源物,这表明凝集素介导的补体激活途径在进化上先于免疫球蛋白途径。因此,尽管在教科书中它是“新”的,但实验证据表明该途径很古老,并且在整个进化过程中都完整地保存了下来。